Wall Street analysts predict that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will post earnings of $0.28 per share for the current quarter, Zacks reports. Three analysts have provided estimates for Sucampo Pharmaceuticals’ earnings, with estimates ranging from $0.21 to $0.35. Sucampo Pharmaceuticals posted earnings of $0.68 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 58.8%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 14th.
According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full year earnings of $1.08 per share for the current fiscal year, with EPS estimates ranging from $1.02 to $1.13. For the next fiscal year, analysts forecast that the firm will post earnings of $1.10 per share, with EPS estimates ranging from $1.05 to $1.14. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The company had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.30 EPS.
A number of research analysts have weighed in on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, October 17th. UBS AG decreased their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Leerink Swann started coverage on Sucampo Pharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $15.00 price objective on the stock. Roth Capital set a $30.00 price objective on Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Maxim Group restated a “buy” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.50.
In related news, insider Jason Patrick Meyenburg bought 4,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was acquired at an average cost of $12.13 per share, with a total value of $48,520.00. Following the purchase, the insider now directly owns 30,228 shares of the company’s stock, valued at $366,665.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of SCMP. Louisiana State Employees Retirement System increased its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 100 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth about $116,000. JPMorgan Chase & Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth about $117,000. Karp Capital Management Corp acquired a new stake in shares of Sucampo Pharmaceuticals during the 1st quarter worth about $119,000. Finally, Pinnacle Associates Ltd. acquired a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth about $122,000. 55.54% of the stock is owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals (SCMP) opened at $10.55 on Monday. The company has a quick ratio of 4.42, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The firm has a market capitalization of $491.12, a price-to-earnings ratio of 7.23, a price-to-earnings-growth ratio of 2.47 and a beta of 1.38. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.55.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Sucampo Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals Inc. and related companies.